The US has announced a 100% tariff on imported generic drugs, effective from August 2028.
The measure, unveiled by President Donald Trump on Tuesday, is designed to compel pharmaceutical manufacturers to relocate production to the United States.
The generic drug levy adds to an existing temporary 10% global tariff, signaling a sustained push toward economic nationalism and supply chain onshoring.
The policy represents a significant escalation in the administration's trade strategy, moving beyond broad-based levies to target specific sectors with prohibitive rates.
By setting the effective date two years in the future, the government provides a transition period for supply chains to adjust, though the long-term impact on drug pricing and availability remains a key uncertainty for investors and healthcare providers.
This announcement follows reports that the White House was preparing a new round of tariffs targeting dozens of countries.
The generic drug levy adds to an existing temporary 10% global tariff, signaling a sustained push toward economic nationalism and supply chain onshoring.